1. Home
  2. MTA vs SDGR Comparison

MTA vs SDGR Comparison

Compare MTA & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

HOLD

Current Price

$6.80

Market Cap

766.4M

Sector

N/A

ML Signal

HOLD

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$11.79

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTA
SDGR
Founded
1983
1990
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
766.4M
850.5M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
MTA
SDGR
Price
$6.80
$11.79
Analyst Decision
Hold
Buy
Analyst Count
1
9
Target Price
$9.00
$21.00
AVG Volume (30 Days)
427.8K
1.3M
Earning Date
05-15-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.14
EPS
N/A
N/A
Revenue
N/A
$255,869,000.00
Revenue This Year
$81.63
$0.76
Revenue Next Year
$62.44
$4.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.29
52 Week Low
$2.83
$10.95
52 Week High
$9.25
$27.63

Technical Indicators

Market Signals
Indicator
MTA
SDGR
Relative Strength Index (RSI) 46.15 47.66
Support Level $6.48 $11.03
Resistance Level $7.21 $13.36
Average True Range (ATR) 0.32 0.68
MACD 0.05 0.06
Stochastic Oscillator 45.39 35.37

Price Performance

Historical Comparison
MTA
SDGR

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: